NYSE$ITGR

Integer Holdings Corporation · Q3 2024 earnings

Q3 2024 earnings · · Investor relations

Briefing

Integer reported strong performance with 3Q24 financial results and raised midpoint of 2024 operating profit and EPS outlook.

Integer Holdings Corporation announced its Third Quarter 2024 results, showcasing a 10% sales growth and a 23% increase in adjusted operating income year to date. The company is raising the midpoint of its full year adjusted operating income outlook by $4 million. The divestiture of Electrochem is expected to close later this month, transforming Integer into a pure-play medical technology company.

  • Integer delivered 10% sales growth year to date.
  • Adjusted operating income increased by 23% year to date.
  • The midpoint of the full year adjusted operating income outlook is raised by $4 million.
  • The sale of the Electrochem business is on track to close later this month.

Headline financials

Total Revenue

$431M

Previous: $405M+6.6%
EPS

$0.99

Previous: $1.27-22.0%
Adjusted Operating Income

$75.6M

No prior period
Adjusted Net Income

$49.8M

No prior period
Adjusted EBITDA

$95.5M

No prior period
EBITDA

$86.3M

No prior period
Capital Expenditures

-$86.3M

Previous: -$82.9M-4.1%
Free Cash Flow

-$50.8M

Previous: -$55.6M+8.6%
Net Income

$35.4M

Previous: $27.3M+30.0%
Operating Income

$58M

Previous: $48.1M+20.7%
Gross Profit

$117M

Previous: $106M+10.4%
Cash & Equivalents

$35.6M

Previous: $32.1M+10.7%
Total Assets

$3.17B

Previous: $2.84B+11.6%
R&D Expense

$11.9M

Previous: $14.5M-18.0%
Stock-Based Comp

$6.12M

Previous: $5.5M+11.3%

Revenue & EPS history

Integer · Revenue · Quarterly

$431M

Q3 2024+6.6%vs Q3 2023
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Revenue by segment

Integer · $266M total across 2 segments · Q1 2023

  • Cardio & Vascular
    $149M
  • Cardiac Rhythm Management & Neuromodulation
    $117M

Forward guidance

Integer expects 2024 sales growth of 10% to 11% with above-market organic sales growth of 7% to 8%.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2024

Historical avgQ3 2024

-0.5%

Avg return

Earnings day

+0.4%

Avg return

5 days after

+2.4%

Avg return

30 days after

41%

25 / 61 earnings

Positive

+16.4%

Q3 2016

Best reaction

-33.2%

Q3 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.3%+2.6%+6.8%
Q4 2025-3.4%+0.7%-2.8%
Q3 2025-33.2%-37.7%-35.8%
Q1 2025+0.8%+5.3%-1.8%
Q4 2024-5.6%-10.8%-19.6%
Q3 2024-0.6%+2.8%+9.2%
Q2 2024-6.2%-2.5%+1.7%
Q1 2024-11.1%-9.4%-0.5%
Q4 2023-5.4%-4.5%+8.3%
Q3 2023+13.6%+16.9%+29.0%
Q2 2023+5.5%+6.5%-5.4%
Q1 2023+1.3%+0.3%-1.2%
Q4 2022+6.0%+2.4%+1.4%
Q3 2022+4.2%+6.4%+20.0%
Q2 2022-0.5%-0.3%-5.2%
Q1 2022-5.1%-1.6%+1.7%
Q4 2021-2.2%-5.5%-7.2%
Q3 2021-1.6%-2.1%-9.0%
Q2 2021-0.9%-3.2%-0.5%
Q1 2021-2.1%-2.6%-5.7%
Q4 2020+9.6%+9.3%+15.5%
Q3 2020-4.1%-4.6%+19.3%
Q2 2020-6.0%-9.3%-0.1%
Q1 2020+6.3%+2.3%+19.0%
Q4 2019+4.9%+1.0%-45.2%
Q3 2019-1.1%-1.1%-2.3%
Q2 2019-3.7%-7.8%-17.3%
Q1 2019+10.7%+11.7%+3.5%
Q4 2018+0.7%+3.0%-1.3%
Q3 2018+13.1%+18.0%+18.9%
Q2 2018-0.9%+0.5%+11.9%
Q1 2018+13.0%+16.8%+17.6%
Q4 2017+16.0%+13.9%+24.6%
Q3 2017-2.7%-4.1%-2.2%
Q2 2017+2.7%+2.0%+0.4%
Q1 2017+2.5%+12.3%+13.9%
Q4 2016-0.7%+2.9%+7.0%
Q3 2016+16.4%+15.8%+51.9%
Q2 2016-30.4%-29.7%-26.5%
Q1 2016-10.4%
Q4 2015-14.3%
Q3 2015+6.4%
Q2 2015+4.0%
Q1 2015-3.5%
Q4 2014+1.0%
Q1 2014-4.0%
Q3 2014+6.8%
Q2 2014+2.9%
Q1 2013-5.1%
Q4 2012+0.1%
Q3 2012-0.5%
Q2 2012+1.3%
Q1 2011-1.4%
Q1 2012+0.6%
Q4 2011-2.8%
Q1 2010-2.8%
Q3 2010-3.6%
Q3 2011-3.6%
Q2 2011-0.8%
Q2 2010-0.8%
Q4 2010-0.8%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro